Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEGCETACOPLAN Cause Breakthrough haemolysis? 67 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 67 reports of Breakthrough haemolysis have been filed in association with PEGCETACOPLAN (Empaveli). This represents 4.9% of all adverse event reports for PEGCETACOPLAN.

67
Reports of Breakthrough haemolysis with PEGCETACOPLAN
4.9%
of all PEGCETACOPLAN reports
1
Deaths
18
Hospitalizations

How Dangerous Is Breakthrough haemolysis From PEGCETACOPLAN?

Of the 67 reports, 1 (1.5%) resulted in death, 18 (26.9%) required hospitalization.

Is Breakthrough haemolysis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEGCETACOPLAN. However, 67 reports have been filed with the FAERS database.

What Other Side Effects Does PEGCETACOPLAN Cause?

Fatigue (135) Visual impairment (125) Haemoglobin decreased (106) Haemolysis (100) Off label use (97) Vitreous floaters (78) Headache (66) Product dose omission issue (59) Uveitis (59) Covid-19 (56)

What Other Drugs Cause Breakthrough haemolysis?

RAVULIZUMAB-CWVZ (120) ECULIZUMAB (100) IPTACOPAN (22) DANICOPAN (8) DEFERASIROX (5)

Which PEGCETACOPLAN Alternatives Have Lower Breakthrough haemolysis Risk?

PEGCETACOPLAN vs PEGFILGRASTIM PEGCETACOPLAN vs PEGFILGRASTIM-APGF PEGCETACOPLAN vs PEGFILGRASTIM-BMEZ PEGCETACOPLAN vs PEGFILGRASTIM-CBQV PEGCETACOPLAN vs PEGFILGRASTIM-JMDB

Related Pages

PEGCETACOPLAN Full Profile All Breakthrough haemolysis Reports All Drugs Causing Breakthrough haemolysis PEGCETACOPLAN Demographics